Related Experiment Video
Updated: Feb 20, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.1K
[Use of loop diuretics in heart failure: Current aspects]
N V Kurlykina1, E M Seredenina1, Yа A Orlova1
1Medical Education Research Center, M.V. Lomonosov Moscow State University, Moscow, Russia.
Terapevticheskii Arkhiv
|October 18, 2017
Summary
Torasemide is a highly effective and safe loop diuretic for symptomatic heart failure patients. Its unique properties improve quality of life by managing fluid and impacting the renin-angiotensin-aldosterone system.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Loop diuretics are primary treatments for symptomatic heart failure.
- Optimizing diuretic therapy is crucial for patient outcomes.
Purpose of the Study:
- To highlight torasemide as a superior loop diuretic option.
- To detail the multifaceted benefits of torasemide in heart failure management.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic properties of torasemide.
- Analysis of clinical data on torasemide's efficacy and safety.
- Evaluation of torasemide's impact on the renin-angiotensin-aldosterone system and myocardial fibrosis.
Main Results:
- Torasemide demonstrates optimal pharmacokinetics and safety.
- It offers additional benefits including renin-angiotensin-aldosterone system blockade and antiadrenergic effects.
- Positive impact on myocardial fibrosis and minimal adverse effects were observed.
Conclusions:
- Torasemide is a leading, safe, and effective loop diuretic for heart failure.
- Sustained-release formulations enhance patient comfort and quality of life.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
388
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
388
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:22Heart Failure VI: Adjunct Therapies
428
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
428
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:22Heart Failure Drugs: β-Blockers
992
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
992